SIRT With Tremelimumab and Durvalumab for Resectable HCC
Active, not recruiting · Phase 1 · NCT05701488
Conditions: Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
At a glance
- Research payments reported, 2025
- $46,189
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- Jiping Wang, MD, PhD (with AstraZeneca, Sirtex Medical)
- Tested
- Durvalumab (drug), Tremelimumab (drug), SIRT (device)
- Dates
- Started 2023-04-21; completion 2027-10-01
- Results posted
- Not yet
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery. The names of the interventions involved in this study are: * Durvalumab (a type of immunotherapy) * Tremelimumab (a type of immunotherapy) * Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere bead)
From ClinicalTrials.gov, last updated 2026-11-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sirtex Medical Inc reported $46,189 in research payments for this study in 2025 (1 payments).
Products named: Sir-Spheres Microspheres
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $46,189
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.